Finance

Lists
Outlook: 63.6% bullish·9.1% bearish
Go to analysis
AVBP:NASDAQ
Arrivent Biopharma Inc
US$ १३.०१
-०.४६%
(-०.०६०) 1D
US$ १३.०१
०.००% (०.००)
After hours
Closed: नोभेम्बर १३, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVBP...
Open
US$ १३.००
High
US$ १३.२४
Low
US$ १२.५९
Mkt. cap
६७.२९ करोड
Avg. vol.
२१.३५ लाख
Volume
६.१६ लाख
52-wk high
US$ ३५.८३
52-wk low
US$ ११.३७
EPS
-US$ ३.६५
Shares outstanding
५.१७ करोड
No. of employees
७७
Open
US$ १३.००
High
US$ १३.२४
Low
US$ १२.५९
Mkt. cap
६७.२९ करोड
Avg. vol.
२१.३५ लाख
Volume
६.१६ लाख
52-wk high
US$ ३५.८३
52-wk low
US$ ११.३७
EPS
-US$ ३.६५
Shares outstanding
५.१७ करोड
No. of employees
७७
News stories
From web sources and news partners
About Arrivent Biopharma Inc
CEO-
Employees७७
Founded२०२१
HeadquartersNewtown Square, पेन्सिलभेनिया, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitearrivent.com
Analyst ratings
Based on 11 analysts giving stock ratings to AVBP in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for AVBP in the last 3 months.
Highest
Current US$ १३.०१
US$ ३०.०० (+१३०.५९%)
Average
US$ २४.२० (+८६.०१%)
Lowest
US$ १५.०० (+१५.३०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
US$ २३.००
+७६.८%
11/11/2026
Supawat Thongthip
Truist Financial
Buy
Maintained
US$ २४.००
+८४.५%
11/10/2026
Boris Peaker
JonesTrading
Buy
Maintained
US$ २२.००
+६९.१%
11/10/2026
Jeff Jones
Oppenheimer
Buy
Maintained
US$ २५.००
+९२.२%
11/10/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ २७.००
+१०७.५%
11/10/2026
Jeet Mukherjee
BTIG
Buy
Maintained
US$ २९.००
+१२२.९%
11/09/2026
Michael Schmidt
Guggenheim
Buy
Maintained
US$ ३०.००
+१३०.६%
10/26/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
-
-
10/25/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
US$ २९.००
+१२२.९%
10/20/2026
Kelly Shi
Jefferies
Buy
Maintained
US$ १८.००
+३८.४%
10/06/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
US$ १५.००
+१५.३%
10/06/2026
Asthika Goonewardene
Leerink Partners
Buy
Maintained
US$ ४५.००
+२४५.९%
08/13/2026
Soumit Roy
JonesTrading
Buy
Maintained
US$ ४५.००
+२४५.९%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
५०.०० लाख
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
३.२२ करोड
३.७६ करोड
४.२३ करोड
३.८९ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६६.४८ लाख
८४.९४ लाख
१.०४ करोड
९४.७९ लाख
Operating expense
३.८८ करोड
४.६१ करोड
५.२७ करोड
४.८४ करोड
Total operating expenses
३.८८ करोड
४.६१ करोड
५.२७ करोड
४.८४ करोड
Operating income
-३.८८ करोड
-४.६१ करोड
-५.२७ करोड
-४.३४ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-३.६० करोड
-४.३३ करोड
-४.९९ करोड
-४.०५ करोड
EBT excluding unusual items
-३.५५ करोड
-४.३३ करोड
-४.९९ करोड
-४.०३ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-३.६० करोड
-४.३३ करोड
-४.९९ करोड
-४.०५ करोड
Net profit margin
-
-
-
-८१०.२४%
Earnings per share
-०.७८
-०.९६
-१.०५
-०.८१
Interest and investment income
३२.७९ लाख
२७.९१ लाख
२७.९८ लाख
३०.६३ लाख
Interest expense
-
-
-
-
Net interest expenses
३२.७९ लाख
२७.९१ लाख
२७.९८ लाख
३०.६३ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू